IBRX ImmunityBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1326110 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY121.2%
TTM net income YoY-218.3%
TTM EPS YoY-158.5%
Revenue 3-yr CAGR589.9%
Net income 3-yr CAGR—
Margins
Gross margin98.8%
Operating margin-150.2%
Net margin-607.8%
FCF margin-162.5%
EBITDA margin-141.1%
Returns
ROE—
ROA-196.7%
ROIC (approx.)—
Asset turnover0.32x
Leverage & solvency
Liabilities / assets288.0%
Debt / equity—
Current ratio4.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.26x
Accruals ratio-145.7%
Payout ratio—
Capex / revenue5.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $113.29M | $14.74M | $622,000 | $240,000 | $934,000 |
| Cost of revenue | $753,000 | $0 | $0 | $0 | — |
| Gross profit | $112.53M | $14.74M | $622,000 | $240,000 | — |
| R&D expense | — | $190.14M | $232.37M | $248.15M | $195.96M |
| SG&A expense | — | $168.78M | $129.62M | $102.71M | $135.26M |
| Operating income | -$256.03M | -$344.18M | -$362.25M | -$351.30M | -$330.28M |
| Interest expense | $60.89M | $114.59M | $128.85M | $63.52M | $14.85M |
| Pretax income | -$351.61M | -$413.64M | -$583.89M | -$417.29M | -$349.84M |
| Income tax | -$135,000 | $0 | -$40,000 | $34,000 | $9,000 |
| Net income | -$351.40M | -$413.56M | -$583.20M | -$416.57M | -$346.79M |
| EBITDA | -$240.50M | -$326.63M | -$343.74M | -$333.04M | -$316.04M |
| EPS (basic) | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 |
| EPS (diluted) | -0.38 | -0.62 | -1.15 | -1.04 | -0.89 |
| Weighted avg. shares (diluted) | 919.86M | 700.44M | 508.64M | 399.90M | 389.23M |
| Balance sheet | |||||
| Cash & equivalents | $88.33M | $143.43M | $265.45M | $104.64M | $181.10M |
| Short-term investments | $154.48M | $6.38M | $1.01M | $2.54M | $136.01M |
| Receivables | $42.57M | $2.36M | $0 | — | — |
| Inventory | $910,000 | $8.27M | $0 | — | — |
| Current assets | $314.88M | $184.59M | $294.08M | $140.58M | $334.35M |
| PP&E, net | $114.26M | $137.09M | $146.08M | $143.66M | $82.86M |
| Goodwill | $910,000 | $910,000 | — | — | — |
| Intangibles | $12.99M | $14.53M | $17.09M | $20.00M | $1.42M |
| Total assets | $501.90M | $382.93M | $504.45M | $362.36M | $468.91M |
| Current liabilities | $61.75M | $54.94M | $58.28M | $500.86M | $369.00M |
| Short-term debt | $1.75M | $1.25M | — | — | — |
| Total liabilities | $1.00B | $871.06M | $1.09B | $812.18M | $712.82M |
| Shareholders' equity | -$500.47M | -$489.10M | -$586.99M | -$447.33M | -$242.17M |
| Shares outstanding | 1.01B | 852.90M | 670.87M | 421.57M | 397.83M |
| Cash flow statement | |||||
| Operating cash flow | -$304.94M | -$391.24M | -$366.76M | -$337.51M | -$274.42M |
| Capital expenditure | $3.85M | $6.89M | $30.58M | $78.16M | $33.56M |
| Free cash flow | -$308.78M | -$398.12M | -$397.34M | -$415.67M | -$307.98M |
| Investing cash flow | -$149.80M | -$12.25M | -$30.47M | $27.30M | -$84.89M |
| Financing cash flow | $400.24M | $281.63M | $558.34M | $233.61M | $505.44M |
| Depreciation & amortization | $15.53M | $17.55M | $18.51M | $18.26M | $14.24M |
| Stock-based compensation | $36.81M | $34.43M | $49.16M | $40.18M | $57.18M |
| Share buybacks | — | — | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.